Related Experiment Videos
Tiludronate: bone pharmacology and safety
J P Bonjour1, P Ammann, A Barbier
1World Health Organization Collaborating Center for Osteoporosis and Bone Disease, Department of Internal Medicine, University Hospital, Geneva, Switzerland.
Bone
|November 1, 1995
Summary
Tiludronate, a bisphosphonate drug, effectively inhibits bone resorption in preclinical studies. This action increases bone mass and mechanical strength, showing its potential for treating bone loss conditions.
Area of Science:
- Pharmacology
- Bone Biology
- Preclinical Research
Background:
- Bisphosphonates are crucial in managing bone resorption disorders.
- Tiludronate is a novel sulfured bisphosphonate with demonstrated anti-resorptive properties.
Purpose of the Study:
- To characterize the pharmacological profile of tiludronate.
- To evaluate its efficacy and safety in preclinical models of bone resorption.
Main Methods:
- In vivo studies in rats, ewes, and dogs using various bone resorption models.
- In vitro studies on bone tissue cultures and osteoclast activity.
- Assessment of bone mass, mechanical resistance, and mineralization.
Main Results:
- Tiludronate demonstrated dose-dependent inhibition of bone resorption across multiple animal models.
- It improved bone mass and mechanical resistance in ovariectomized osteoporotic rats.
- In vitro, tiludronate reduced calcium release and collagen degradation without impairing osteoclast precursor function.
Conclusions:
- Tiludronate is a safe and effective bisphosphonate with a wide therapeutic margin.
- Preclinical data support its use in managing conditions with excessive bone resorption.
- Its mechanism involves mature osteoclast function and detachment from bone matrix.